158 related articles for article (PubMed ID: 25029973)
1. Application of a policy framework for the public funding of drugs for rare diseases.
Winquist E; Coyle D; Clarke JT; Evans GA; Seager C; Chan W; Martin J
J Gen Intern Med; 2014 Aug; 29 Suppl 3(Suppl 3):S774-9. PubMed ID: 25029973
[TBL] [Abstract][Full Text] [Related]
2. An evaluation framework for funding drugs for rare diseases.
Winquist E; Bell CM; Clarke JT; Evans G; Martin J; Sabharwal M; Gadhok A; Stevenson H; Coyle D
Value Health; 2012; 15(6):982-6. PubMed ID: 22999151
[TBL] [Abstract][Full Text] [Related]
3. Engaging the Canadian public on reimbursement decision-making for drugs for rare diseases: a national online survey.
Polisena J; Burgess M; Mitton C; Lynd LD
BMC Health Serv Res; 2017 May; 17(1):372. PubMed ID: 28549479
[TBL] [Abstract][Full Text] [Related]
4. Budget impact of rare diseases: proposal for a theoretical framework based on evidence from Bulgaria.
Iskrov G; Jessop E; Miteva-Katrandzhieva T; Stefanov R
Georgian Med News; 2015 May; (242):46-53. PubMed ID: 26042447
[TBL] [Abstract][Full Text] [Related]
5. What Does the New Ontario Pharmacare Plan offer Children and Young Adults with Rare Disorders?
Rawson N
J Popul Ther Clin Pharmacol; 2017 Dec; 24(3):90-98. PubMed ID: 29432671
[TBL] [Abstract][Full Text] [Related]
6. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
Zelei T; Molnár MJ; Szegedi M; Kaló Z
Orphanet J Rare Dis; 2016 Jun; 11(1):72. PubMed ID: 27259284
[TBL] [Abstract][Full Text] [Related]
7. Do Reimbursement Recommendations by the Canadian Agency for Drugs and Technology in Health Translate Into Coverage Decisions for Orphan Drugs in the Canadian Province of Ontario?
Fontrier AM; Kanavos P
Value Health; 2023 Jul; 26(7):1011-1021. PubMed ID: 36889379
[TBL] [Abstract][Full Text] [Related]
8. Comparative policy analysis of national rare disease funding policies in Australia, Singapore, South Korea, the United Kingdom and the United States: a scoping review.
Ng QX; Ong C; Chan KE; Ong TSK; Lim IJX; Tang ASP; Chan HW; Koh GCH
Health Econ Rev; 2024 Jun; 14(1):42. PubMed ID: 38896399
[TBL] [Abstract][Full Text] [Related]
9. Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes.
Morrell L; Wordsworth S; Fu H; Rees S; Barker R
BMC Health Serv Res; 2017 Aug; 17(1):613. PubMed ID: 28854927
[TBL] [Abstract][Full Text] [Related]
10. Regulatory approval and public drug plan listing of new drugs for rare disorders in Canada and New Zealand.
Rawson NSB
J Popul Ther Clin Pharmacol; 2020 Jun; 27(2):e58-e67. PubMed ID: 32543163
[TBL] [Abstract][Full Text] [Related]
11. Stated and Revealed Preferences for Funding New High-Cost Cancer Drugs: A Critical Review of the Evidence from Patients, the Public and Payers.
MacLeod TE; Harris AH; Mahal A
Patient; 2016 Jun; 9(3):201-22. PubMed ID: 26370257
[TBL] [Abstract][Full Text] [Related]
12. Health technology assessment of drugs for rare diseases: insights, trends, and reasons for negative recommendations from the CADTH common drug review.
Janoudi G; Amegatse W; McIntosh B; Sehgal C; Richter T
Orphanet J Rare Dis; 2016 Dec; 11(1):164. PubMed ID: 27908281
[TBL] [Abstract][Full Text] [Related]
13. A National Approach to Reimbursement Decision-Making on Drugs for Rare Diseases in Canada? Insights from Across the Ponds.
Short H; Stafinski T; Menon D
Healthc Policy; 2015 May; 10(4):24-46. PubMed ID: 26142357
[TBL] [Abstract][Full Text] [Related]
14. Expensive drugs for rare disorders: to treat or not to treat? The case of enzyme replacement therapy for mucopolysaccharidosis VI.
Schlander M; Beck M
Curr Med Res Opin; 2009 May; 25(5):1285-93. PubMed ID: 19366306
[TBL] [Abstract][Full Text] [Related]
15. A discrete choice experiment investigating preferences for funding drugs used to treat orphan diseases: an exploratory study.
Mentzakis E; Stefanowska P; Hurley J
Health Econ Policy Law; 2011 Jul; 6(3):405-33. PubMed ID: 21205401
[TBL] [Abstract][Full Text] [Related]
16. Drugs for exceptionally rare diseases: do they deserve special status for funding?
Hughes DA; Tunnage B; Yeo ST
QJM; 2005 Nov; 98(11):829-36. PubMed ID: 16203824
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with positive and negative recommendations for cancer and non-cancer drugs for rare diseases in Canada.
Nagase FNI; Stafinski T; Sun J; Jhangri G; Menon D
Orphanet J Rare Dis; 2019 Jun; 14(1):127. PubMed ID: 31174574
[TBL] [Abstract][Full Text] [Related]
18. Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration.
Chan K; Nam S; Evans B; de Oliveira C; Chambers A; Gavura S; Hoch J; Mercer RE; Dai WF; Beca J; Tadrous M; Isaranuwatchai W
BMJ Open; 2020 Jan; 10(1):e032884. PubMed ID: 31915169
[TBL] [Abstract][Full Text] [Related]
19. In vitro fertilization and multiple pregnancies: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(18):1-63. PubMed ID: 23074488
[TBL] [Abstract][Full Text] [Related]
20. Impact of a novel prioritization framework on clinician-led oncology drug submissions.
Keech J; Beca J; Eisen A; Kennedy E; Kim J; Kouroukis CT; Darling G; Ferguson SE; Finelli A; Petrella TM; Perry JR; Chan K; Gavura S
Curr Oncol; 2019 Apr; 26(2):e155-e161. PubMed ID: 31043821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]